New Clinical Practice Guidelines Developed For Juvenile Idiopathic Arthritis

Main Category: Arthritis / Rheumatology
Also Included In: Pediatrics / Children’s Health
Article Date: 31 Mar 2011 – 0:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  
<!– rate icon rate article



Patient / Public:not yet rated

Healthcare Prof:not yet rated

The American College of Rheumatology has developed new guidelines for starting and monitoring treatments for children with juvenile idiopathic arthritis. These are the first JIA guidelines endorsed by the ACR, with the goal of broad acceptance within the rheumatology community.

Created as a guide for health care providers, the guidelines focus on the initiation and safety monitoring of multiple medications used in the treatment of JIA, including:

Osteoarthritis: What You Know Could Save Your Joints!

Main Category: Arthritis / Rheumatology
Also Included In: Bones / Orthopedics;  Rehabilitation / Physical Therapy
Article Date: 31 Mar 2011 – 3:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  
<!– rate icon rate article



Patient / Public:not yet rated

Healthcare Prof:not yet rated

According to the Arthritis Foundation, 27 million Americans live with osteoarthritis, the most common form of arthritis which involves a mechanical “wear and tear” of the cartilage that lines the inside of our joints and which, over time, can result in damage to the connective tissue and bone around the joint. The more you know about the condition, the greater your chance for success in finding the help that you need.

Merz Pharmaceuticals Announces New Centers For Medicare And Medicaid Billing Q-Code For Xeomin(R) (IncobotulinumtoxinA)

Main Category: Medicare / Medicaid / SCHIP
Also Included In: Medical Practice Management
Article Date: 31 Mar 2011 – 2:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  
<!– rate icon rate article

Patient / Public:not yet rated

Healthcare Prof:not yet rated

Merz Pharmaceuticals, LLC announced today that the Centers for Medicare and Medicaid Services (CMS) has granted a unique Healthcare Common Procedure Coding System (HCPCS) billing code, Q2040, for Xeomin®(incobotulinumtoxinA). Merz expects that this unique billing code, which will become effective on April 1, 2011, will help simplify the billing and reimbursement process for prescribers of XEOMIN.

Advanced Prostate Cancer Drug Provenge $93,000 Per Patient Likely To Be Covered By Medicare

Editor’s Choice
Main Category: Prostate / Prostate Cancer
Also Included In: Medicare / Medicaid / SCHIP;  Urology / Nephrology;  Cancer / Oncology
Article Date: 31 Mar 2011 – 9:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  
<!– rate icon rate article

Patient / Public:not yet rated

Healthcare Prof:not yet rated

Article Opinions: 1 posts

Medicare has indicated that it proposes to cover the $93,000 cost per patient for a four month course of advanced prostate cancer vaccine Provenge (Sipuleucel-T). Provenge is a therapeutic cancer vaccine designed to prolong the life of patients with advanced to late stage prostate cancer, metastatic, asymptomatic, hormone-refractory prostate cancer. Provenge makes it possible for the patient’s immune system to identify and target prostate cancer cells.

Global Health Ventures Announces Interim Data From The European Clinical Trails Of X-Excite Vs. Viagra

Main Category: Clinical Trials / Drug Trials
Also Included In: Erectile Dysfunction / Premature Ejaculation
Article Date: 31 Mar 2011 – 1:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  
<!– rate icon rate article

Patient / Public:4 stars

4 (2 votes)

Healthcare Prof:not yet rated

Global Health Ventures Inc. (OTCBB:GHLV), a specialty pharmaceutical company, is pleased to announce the interim results of the clinical trials conducted in Europe under the EMEA guideline protocols for its lead therapeutic drug, X-Excite.

Experts Exchange Information And Updates On Spondyloarthritis

Main Category: Arthritis / Rheumatology
Also Included In: Bones / Orthopedics
Article Date: 30 Mar 2011 – 0:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  
<!– rate icon rate article



Patient / Public:not yet rated

Healthcare Prof:not yet rated

Spondyloarthritis (SpA) is a group of inflammatory conditions causing spine and joint pain and deformity, mostly in young men. Important updates on the epidemiology, diagnosis, and treatment of SpA are presented in the April issue of The American Journal of the Medical Sciences (AJMS), official journal of the Southern Society for Clinical Investigation. The journal is published by Lippincott Williams Wilkins, a part of Wolters Kluwer Health.

Draft NICE Guidance Does Not Recommend Abatacept For Second-line Use In Rheumatoid Arthritis

Main Category: Arthritis / Rheumatology
Article Date: 30 Mar 2011 – 3:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  
<!– rate icon rate article



Patient / Public:not yet rated

Healthcare Prof:not yet rated

The National Institute for Health and Clinical Excellence (NICE) has today (30 March 2011) opened a consultation on draft guidance which does not recommend abatacept (Orencia, Bristol-Myers Squibb), in combination with methotrexate, for the treatment of moderate to severe active rheumatoid arthritis in adults whose disease has responded inadequately to one or more conventional non-biological disease modifying anti-rheumatic drugs (DMARDs) including methotrexate.

Benefits Of Exercise For Arthritis Suffers

Main Category: Arthritis / Rheumatology
Also Included In: Sports Medicine / Fitness
Article Date: 28 Mar 2011 – 12:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  
<!– rate icon rate article



Patient / Public:5 stars

5 (1 votes)

Healthcare Prof:not yet rated

An estimated 50 million adults in the United States suffer from arthritis. According to the Centers for Disease Control, one of the best ways to combat the onset of arthritis as well as to control pain and improve function is through exercise.

Artimplant: Artelon(R) CMC Soft Cleared For Marketing In Europe

Main Category: Bones / Orthopedics
Also Included In: Arthritis / Rheumatology;  Regulatory Affairs / Drug Approvals
Article Date: 28 Mar 2011 – 5:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  
<!– rate icon rate article



Patient / Public:not yet rated

Healthcare Prof:not yet rated

In collaboration with Small Bone Innovations (SBi), Artimplant has developed a new product in the Artelon® Spacer range with a similar user-friendly textile design to Artelon® Tissue Reinforcement (ATR). The product, Artelon® CMC Soft, has been granted CE-approval by the certification body Lloyd’s and has thus been granted clearance for marketing in Europe.

Rheumatology Program Expands At NewYork-Presbyterian/Columbia

Main Category: Arthritis / Rheumatology
Article Date: 24 Mar 2011 – 12:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  
<!– rate icon rate article



Patient / Public:not yet rated

Healthcare Prof:not yet rated

The rheumatology program at NewYork-Presbyterian Hospital/Columbia University Medical Center is expanding with the addition of one of the nation’s leading rheumatologists, the creation of a new integrated Arthritis Center, and plans for additional disease-specific centers.

Dr. Joan Bathon has been appointed director of the Division of Rheumatology at NewYork-Presbyterian Hospital/Columbia University Medical Center and professor of medicine at Columbia University College of Physicians and Surgeons. Previously, she was deputy director of the Division of Rheumatology and director of the Arthritis Center at Johns Hopkins.